• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Orgenesis Inc.

    1/19/23 3:17:46 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGS alert in real time by email
    SC 13G 1 tm233912d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    Information Statement Pursuant to Rules 13d-1 and 13d-2
    Under the Securities Exchange Act of 1934
    (Amendment No.     )*
     
      Orgenesis Inc.  
    (Name of Issuer)
     
      Common Stock, $0.0001 par value per share (the “Common Stock”)  
    (Title of Class of Securities)
     
      68619K204  
      (CUSIP Number)  
         
      January 10, 2023  
      (Date of Event Which Requires Filing of the Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨      Rule 13d-1(b)
    x
         Rule 13d-1(c)
    ¨
         Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 68619K204 13G Page 2 of 8 Pages

     

    1.

    NAME OF REPORTING PERSON

     

    NewTech Investment Holdings, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

    3. SEC USE ONLY  
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5.

    SOLE VOTING POWER

    0

    6.

    SHARED VOTING POWER

     

    1,623,376 shares  

    7.

    SOLE DISPOSITIVE POWER

    0

    8.

    SHARED DISPOSITIVE POWER

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0%1

    12.

    TYPE OF REPORTING PERSON

    OO

     

     

     

    1The percentages reported in this Schedule 13G are based upon 27,169,131 shares of Common Stock outstanding (comprising (i) 25,545,755 shares of Common Stock outstanding as of November 10, 2022 (according to the issuer’s Current Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022) and (ii) 1,623,376 shares issuable upon the conversion of certain loans held by the Reporting Persons). All of the other numbers and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing.

     

     

    CUSIP No. 68619K204 13G Page 3 of 8 Pages

     

    1.

    NAME OF REPORTING PERSON

     

    Guy Hoffman

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

    3. SEC USE ONLY  
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5.

    SOLE VOTING POWER

    0

    6.

    SHARED VOTING POWER

     

    1,623,376 shares  

    7.

    SOLE DISPOSITIVE POWER

    0

    8.

    SHARED DISPOSITIVE POWER

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0%

    12.

    TYPE OF REPORTING PERSON

    IN; HC

     

     

    CUSIP No. 68619K204 13G Page 4 of 8 Pages

     

    Item 1(a)Name of Issuer

    Orgenesis Inc. (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices
    20271 Goldenrod Lane, Germantown, MD 20876

     

    Item 2(a)Name of Person Filing
    This Schedule 13G is being jointly filed by NewTech Investment Holdings, LLC (“NewTech”) and Guy Hoffman (“Hoffman” and, together with NewTech, the “Reporting Persons”) with respect to shares of common stock of the Issuer owned by NewTech.

     

    Hoffman is the Managing Member of NewTech.

     

    The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

     

    Item 2(b)Address of Principal Business Office
    The address of the principal business office of each of the Reporting Persons is 3642 Underwood Street, Houston, Texas 77025.

     

    Item 2(c)Citizenship
    NewTech is organized as a limited liability company under the laws of the State of Delaware. Hoffman is a U.S. citizen.

     

    Item 2(d)Title of Class of Securities
    Common Stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number
    68619K204

     

     

    CUSIP No. 68619K204 13G Page 5 of 8 Pages

     

    Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Exchange Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Exchange Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act;

     

    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

    CUSIP No. 68619K204 13G Page 6 of 8 Pages

     

    Item 4Ownership

     

    A.NewTech Investment Holdings, LLC

     

    (a)NewTech may be deemed to beneficially own 1,623,376 shares of Common Stock.

     

    (b)The number of shares NewTech may be deemed to beneficially own constitutes approximately 6.0% of the Common Stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 1,623,376

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 1,623,376

     

    B.Guy Hoffman

     

    (a)Hoffman may be deemed to beneficially own 1,623,376 shares of Common Stock.

     

    (b)The number of shares Hoffman may be deemed to beneficially own constitutes approximately 6.0% of the Common Stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 1,623,376

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 1,623,376

     

    Item 5Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

    See Item 2 above

     

    Item 8Identification and Classification of Members of the Group

    Not Applicable

     

     

    CUSIP No. 68619K204 13G Page 7 of 8 Pages

     

    Item 9Notice of Dissolution of Group

    Not Applicable

     

    Item 10Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 68619K204 13G Page 8 of 8 Pages

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 19th day of January, 2023.

     

    NewTech Investment Holdings, LLC  guy hoffman
          
          
    By: /s/ Guy Hoffman  /s/ Guy Hoffman
      Guy Hoffman, Managing Member  Guy Hoffman

     

     

    Get the next $ORGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORGS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ORGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orgenesis Provides Third Quarter 2024 Business Update

      GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentralized approach. This model is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. We are dedicated to expanding our clinical initiatives and deepening gl

      11/13/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Commences Trading on OTCQX® Best Market

      Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficienc

      10/21/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Announces Reverse Stock Split

      GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq C

      9/23/24 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Safier Jacob bought $16,883 worth of shares (30,000 units at $0.56) and sold $16,259 worth of shares (30,000 units at $0.54) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/4/24 6:48:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $3,332 worth of shares (10,100 units at $0.33) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:32:21 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $213,280 worth of shares (365,140 units at $0.58) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:31:52 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Financials

    Live finance-specific insights

    See more
    • Orgenesis Provides Second Quarter 2024 Business Update

      GERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended June 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "After more than a decade of parallel efforts—on one hand, establishing robust capabilities in cell therapy production by initially serving the industry in a centralized manner and later integrating these capabilities into a decentralized platform, and on the other, forming partnerships through joint ve

      8/8/24 4:05:00 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

      GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners ("Metalmark"), for the acquisition of its approximate 25% stake in Octomera LLC ("Octomera"), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027,

      1/31/24 9:15:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Provides Business Update for Second Quarter of 2023

      Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, "We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform. We recently rebranded the POC Servic

      8/11/23 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)

      3 - Orgenesis Inc. (0001460602) (Issuer)

      3/18/25 4:06:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Vider Itzhak

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:24 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Adler Yaron

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:29 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Leadership Updates

    Live Leadership Updates

    See more
    • Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

      GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced therapeutic POCare services and facilities supply business, Octomera. The appointment of Gerhard Bauer as the Vice President of Global Product Implementation at Octomera has been made to enhance the existing process development, regulatory, engineering, equipment, and data/technical service offering and POCare Center hubs. He is also an active contributor to the evolution of the flexible facilities format, Octomera Mobile Process Labs & Units (OMPULs) and network, which allow the

      9/6/23 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

      GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023. Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical devic

      7/13/23 8:30:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education

      New York, March 08, 2021 (GLOBE NEWSWIRE) -- - Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here - Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs click here - QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) updates on Opemiska drill progress and names new independent director click here - AIM ImmunoTech Inc (NYSEAMERICAN:AIM) doses first healthy subject in intranasal Ampligen coronavirus study click here - Alpine 4 Technologies Inc (OTCQB:ALPP) say

      3/8/21 2:36:14 PM ET
      $TCON
      $ORGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ORGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:51:18 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:50:26 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Orgenesis Inc. (Amendment)

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      2/14/24 8:16:04 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Orgenesis Inc.

      25-NSE - Orgenesis Inc. (0001460602) (Subject)

      5/8/25 5:21:49 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Inc. filed SEC Form 8-K: Other Events

      8-K - Orgenesis Inc. (0001460602) (Filer)

      4/22/25 4:30:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Orgenesis Inc.

      NT 10-K - Orgenesis Inc. (0001460602) (Filer)

      4/1/25 4:05:18 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care